Iteos Therapeutics Inc
NASDAQ:ITOS
Iteos Therapeutics Inc
Stock-Based Compensation
Iteos Therapeutics Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
Stock-Based Compensation
$27m
|
CAGR 3-Years
85%
|
CAGR 5-Years
201%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$872m
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$739.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Iteos Therapeutics Inc
Glance View
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. The company is headquartered in Watertown, Massachusetts and currently employs 94 full-time employees. The company went IPO on 2020-07-24. The firm is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The firm's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The firm is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
See Also
What is Iteos Therapeutics Inc's Stock-Based Compensation?
Stock-Based Compensation
27m
USD
Based on the financial report for Dec 31, 2023, Iteos Therapeutics Inc's Stock-Based Compensation amounts to 27m USD.
What is Iteos Therapeutics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
201%
Over the last year, the Stock-Based Compensation growth was 25%. The average annual Stock-Based Compensation growth rates for Iteos Therapeutics Inc have been 85% over the past three years , 201% over the past five years .